Dieter Weinand (MS ’87) was appointed Chairman of the Board of Directors at Replimune Group Inc. (REPL), a biotechnology company developing oncolytic immuno-gene therapies. Weinand was formerly the Executive Vice President of Primary Care and a member of the Executive Committee at Sanofi, a global leader in healthcare. Prior to that he was the President of The Pharmaceuticals Division and member of the Management Board at Bayer AG. He has also held executive positions at Pfizer and Bristol Myers Squibb.
